Phase 2 Breast Cancer Trial, Recruiting NCT07330544 Sponsor: Zhejiang Cancer Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07330544
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have signed an informed consent form agreeing to take part in the study
  • Women aged 18 or older
  • People whose general physical health and ability to carry out daily activities is rated as good to fully active (scored 0 or 1 on a standard medical scale)
  • People whose life expectancy is at least 3 months
  • People diagnosed with breast cancer that is hormone receptor (HR) positive and HER2 negative, confirmed by tissue testing
  • People whose breast cancer has come back or spread and who have already received at least one round of hormone therapy plus a CDK4/6 inhibitor treatment; or people whose cancer came back during, or within 12 months of finishing, this combination as a preventive (adjuvant) therapy
  • People who have not yet received chemotherapy or antibody-drug conjugate (ADC) therapy for their metastatic disease
  • People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines (RECIST 1.1)
  • People with no known active spread of cancer to the brain or the lining around the brain or spinal cord
  • People whose blood, kidney, and liver test results fall within the required ranges in the week before starting the study (confirm with trial site for exact values)
  • People whose heart function tests show the heart is pumping adequately and the heart's electrical activity is within a normal range (confirm with trial site for exact values)
  • Women who have not yet reached menopause and agree to use a hormone-suppressing injection (LHRH agonist) alongside the study treatment
  • People who are able to become pregnant and agree to use effective contraception, or to abstain from sexual activity, during the study and for 3 months after finishing treatment

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cancer has spread to internal organs in a way that is causing serious symptoms, or where the treating doctor considers hormone-based treatment unsuitable
  • People who currently have, or have had in the past, cancer spread to the brain or the membranes surrounding the brain or spinal cord
  • People who have previously been treated with certain targeted therapies, including SERDs (such as fulvestrant), HDAC inhibitors, certain multi-target kinase inhibitors, or PAM pathway inhibitors such as PI3K, AKT, or mTOR inhibitors (confirm with trial site for the full list)
  • People with a known allergy to any of the study drugs or to related drug types (confirm with trial site for the full list)
  • People who are pregnant or breastfeeding
  • People who have another active cancer, unless it has been fully treated with no signs of return
  • People who have fluid around the heart requiring drainage, significant fluid around the lungs causing symptoms, or fluid in the abdomen
  • People whom the treating doctor considers unsuitable for the trial for other medical reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

Contact this trial

Phone: 18867509858

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
24 November 2025
Est. completion
25 November 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ORR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov